Journal Publications

Export 135 results:
Author Title Type [ Year(Asc)]
Filters: Type is Journal Article  [Clear All Filters]
Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery. Engsig F, Zangerle R, Katsarou O, Dabis F, Reiss P, Gill J, Porter K, Sabin C, Riordan A, Fätkenheuer G et al. Clin Infect Dis, 2014 May, Volume 58, Issue 9, p.1312-21, (2014)
Response to antiretroviral therapy (ART): comparing women with previous use of zidovudine monotherapy (ZDVm) in pregnancy with ART naïve women. Huntington S, Thorne C, Anderson J, Newell M, Taylor G, Pillay D, Hill T, Tookey P and Sabin C. BMC Infect Dis, 2014 Mar 04, Volume 14, p.127, (2014)
Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe. De Luca A, Dunn D, Zazzi M, Camacho R, Torti C, Fanti I, Kaiser R, Sönnerborg A, Codoñer F, Van Laethem K et al. J Infect Dis, 2013 Apr 15, Volume 207, Issue 8, p.1216-20, (2013)
Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues. Santoro M, Sabin C, Forbici F, Bansi L, Dunn D, Fearnhill E, Boumis E, Nicastri E, Antinori A, Palamara G et al. HIV Med, 2013 Oct, Volume 14, Issue 9, p.571-7, (2013)
Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring. Winston A, Jose S, Gibbons S, Back D, Stöhr W, Post F, Fisher M, Gazzard B, Nelson M, Gilson R et al. J Antimicrob Chemother, 2013 Jun, Volume 68, Issue 6, p.1354-9, (2013)
HIV-1 subtype and virological response to antiretroviral therapy: a confirmatory analysis. Dolling D, Dunn D, Geretti A and Sabin C. Clin Infect Dis, 2013 Jan, Volume 56, Issue 1, p.162-3, (2013)
HLA B*5701 status, disease progression, and response to antiretroviral therapy. . AIDS, 2013 Oct 23, Volume 27, Issue 16, p.2587-92, (2013)
The impact of HIV-1 reverse transcriptase polymorphisms on responses to first-line nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-1-infected adults. Mackie N, Dunn D, Dolling D, Garvey L, Harrison L, Fearnhill E, Tilston P, Sabin C and Geretti A. AIDS, 2013 Sep 10, Volume 27, Issue 14, p.2245-53, (2013)
The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era. Mocroft A, Furrer H, Miro J, Reiss P, Mussini C, Kirk O, Abgrall S, Ayayi S, Bartmeyer B, Braun D et al. Clin Infect Dis, 2013 Oct, Volume 57, Issue 7, p.1038-47, (2013)
Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study. Dolling D, Dunn D, Sutherland K, Pillay D, Mbisa J, Parry C, Post F, Sabin C and Cane P. J Antimicrob Chemother, 2013 Oct, Volume 68, Issue 10, p.2339-43, (2013)
Predictors of CD4(+) T-cell counts of HIV type 1-infected persons after virologic failure of all 3 original antiretroviral drug classes. Costagliola D, Ledergerber B, Torti C, van Sighem A, Podzamczer D, Mocroft A, Dorrucci M, Masquelier B, De Luca A, Jansen K et al. J Infect Dis, 2013 Mar 01, Volume 207, Issue 5, p.759-67, (2013)
Predictors of pregnancy and changes in pregnancy incidence among HIV-positive women accessing HIV clinical care. Huntington S, Thorne C, Bansi L, Anderson J, Newell M, Taylor G, Pillay D, Hill T, Tookey P and Sabin C. AIDS, 2013 Jan 02, Volume 27, Issue 1, p.95-103, (2013)
Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). Mocroft A, Lundgren J, Sabin M, Monforte A, Brockmeyer N, Casabona J, Castagna A, Costagliola D, Dabis F, De Wit S et al. PLoS Med, 2013, Volume 10, Issue 9, p.e1001510, (2013)
Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: the effect of a nucleoside backbone. Waters L, Bansi L, Asboe D, Pozniak A, Smit E, Orkin C, Fearnhill E, Dunn D and Phillips A. Antivir Ther, 2013, Volume 18, Issue 2, p.213-9, (2013)
All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. Lewden C, Bouteloup V, De Wit S, Sabin C, Mocroft A, Wasmuth J, van Sighem A, Kirk O, Obel N, Panos G et al. Int J Epidemiol, 2012 Apr, Volume 41, Issue 2, p.433-45, (2012)
Baseline kidney function as predictor of mortality and kidney disease progression in HIV-positive patients. Ibrahim F, Hamzah L, Jones R, Nitsch D, Sabin C and Post F. Am J Kidney Dis, 2012 Oct, Volume 60, Issue 4, p.539-47, (2012)
Biomarkers to monitor safety in people on art and risk of mortality. Bansi L, Gazzard B, Post F, Phillips A, Johnson M, Hill T, Gilson R, Leen C, Walsh J, Fisher M et al. J Acquir Immune Defic Syndr, 2012 May 01, Volume 60, Issue 1, p.51-8, (2012)
Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe. Nakagawa F, Lodwick R, Costagliola D, van Sighem A, Torti C, Podzamczer D, Mocroft A, Ledergerber B, Dorrucci M, Cozzi-Lepri A et al. J Acquir Immune Defic Syndr, 2012 Mar 01, Volume 59, Issue 3, p.294-9, (2012)
CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE. Young J, Psichogiou M, Meyer L, Ayayi S, Grabar S, Raffi F, Reiss P, Gazzard B, Sharland M, Gutiérrez F et al. PLoS Med, 2012, Volume 9, Issue 3, p.e1001194, (2012)
Comparison of CKD-EPI and MDRD to estimate baseline renal function in HIV-positive patients. Ibrahim F, Hamzah L, Jones R, Nitsch D, Sabin C and Post F. Nephrol Dial Transplant, 2012 Jun, Volume 27, Issue 6, p.2291-7, (2012)
Does discordancy between the CD4 count and CD4 percentage in HIV-positive individuals influence outcomes on highly active antiretroviral therapy? Gompels M, Dunn D, Phillips A, Dooley D, Thomas A, Anderson J, Post F, Pillay D, Gazzard B, Hill T et al. J Infect Dis, 2012 Feb 15, Volume 205, Issue 4, p.540-7, (2012)
Evaluating the extent of potential resistance to pre-exposure prophylaxis within the UK HIV-1-infectious population of men who have sex with men. Dolling D, Phillips A, Delpech V, Pillay D, Cane P, Crook A, Shepherd J, Fearnhill E, Hill T and Dunn D. HIV Med, 2012 May, Volume 13, Issue 5, p.309-14, (2012)
Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. Barber T, Harrison L, Asboe D, Williams I, Kirk S, Gilson R, Bansi L, Pillay D and Dunn D. J Antimicrob Chemother, 2012 Apr, Volume 67, Issue 4, p.995-1000, (2012)
Hepatitis B virus infection in HIV-positive individuals in the UK collaborative HIV cohort (UK CHIC) study. Price H, Bansi L, Sabin C, Bhagani S, Burroughs A, Chadwick D, Dunn D, Fisher M, Main J, Nelson M et al. PLoS One, 2012, Volume 7, Issue 11, p.e49314, (2012)
Non-uptake of highly active antiretroviral therapy among patients with a CD4 count < 350 cells/μL in the UK. Kober C, Johnson M, Fisher M, Hill T, Anderson J, Bansi L, Gompels M, Palfreeman A, Dunn D, Gazzard B et al. HIV Med, 2012 Jan, Volume 13, Issue 1, p.73-8, (2012)